Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2018

August 31, 2018

CRANBURY, N.J., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at two investor conferences in September.

- Bradley Campbell, President and Chief Operating Officer, and Chip Baird, Chief Financial Officer, will present a corporate overview and fireside chat at the Baird 2018 Global Healthcare Conference on Wednesday, September 5, 2018 at 9:40 a.m. E.T.

- John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference in London, UK on Wednesday, September 12, 2018 at 11:25 a.m. UTC (7:25 a.m. ET)

A live webcast of both presentations can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events-and-presentations, and will be archived for 90 days.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold™ (migalastat), an oral precision medicine for people living with Fabry disease who have amenable *GLA* variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at www.amicusrx.com.

INDICATIONS AND USAGE
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (*GLA*) variant based on *in vitro* assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

U.S. IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS
The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia.

USE IN SPECIFIC POPULATIONS
There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.

It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.

Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.

The safety and effectiveness of Galafold have not been established in pediatric patients.

To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/galafold.pdf.

CONTACTS:

Investors:
Amicus Therapeutics
Andrew Faughnan
Associate Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media / Multimedia Assets:
Pure Communications
Jennifer Paganelli
jpaganelli@purecommunications.com

(347) 658-8290

FOLD–G

Source: Amicus Therapeutics, Inc.